과제정보
The authors thank each of the study subjects for their participation.
참고문헌
- Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol 2022;97:818-829
- Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 2016;68:1323-1341
- Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79:1817-1822
- Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 2014;99:1479-1485
- Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-2445
- Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570-1579
- Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015;36:244-251
- Guo Y, Li X, Wang Y. State of the art: quantitative cardiac MRI in cardiac amyloidosis. J Magn Reson Imaging 2022;56:1287-1301
- Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA 2020;324:79-89
- Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-4549
- Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017;19:75
- Lin L, Li X, Feng J, Shen KN, Tian Z, Sun J, et al. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. J Cardiovasc Magn Reson 2018;20:2
- Yim D, Riesenkampff E, Caro-Dominguez P, Yoo SJ, Seed M, Grosse-Wortmann L. Assessment of diffuse ventricular myocardial fibrosis using native T1 in children with repaired tetralogy of fallot. Circ Cardiovasc Imaging 2017;10:e005695
- Li X, Huang S, Han P, Zhou Z, Azab L, Lu M, et al. Nonenhanced chemical exchange saturation transfer cardiac magnetic resonance imaging in patients with amyloid light-chain amyloidosis. J Magn Reson Imaging 2022;55:567-576
- Chamling B, Bietenbeck M, Drakos S, Korthals D, Vehof V, Stalling P, et al. A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis. Sci Rep 2022;12:21755
- Leone O, Longhi S, Quarta CC, Ragazzini T, De Giorgi LB, Pasquale F, et al. New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. Amyloid 2012;19:99-105
- Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, et al. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J 2022;43:4722-4735
- Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc Imaging 2018;11:152-154
- Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging 2021;14:189-199
- Bodez D, Ternacle J, Guellich A, Galat A, Lim P, Radu C, et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid 2016;23:158-167
- Sengupta PP, Tajik AJ, Chandrasekaran K, Khandheria BK. Twist mechanics of the left ventricle: principles and application. JACC Cardiovasc Imaging 2008;1:366-376
- Cohen OC, Ismael A, Pawarova B, Manwani R, Ravichandran S, Law S, et al. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. Eur Heart J 2022;43:333-341
- Cuddy SAM, Jerosch-Herold M, Falk RH, Kijewski MF, Singh V, Ruberg FL, et al. Myocardial composition in light-chain cardiac amyloidosis more than 1 year after successful therapy. JACC Cardiovasc Imaging 2022;15:594-603
- Zheng Y, Huang S, Xie B, Zhang N, Liu Z, Tse G, et al. Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy. Curr Probl Cardiol 2023;48:101536
- Kim J, Hong YJ, Han K, Kim JY, Lee HJ, Hur J, et al. Chemotherapy-related cardiac dysfunction: quantitative cardiac magnetic resonance image parameters and their prognostic implications. Korean J Radiol 2023;24:838-848
- Edwards CV, Rao N, Bhutani D, Mapara M, Radhakrishnan J, Shames S, et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood 2021;138:2632-2641
- Cuddy SAM, Bravo PE, Falk RH, El-Sady S, Kijewski MF, Park MA, et al. Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease? JACC Cardiovasc Imaging 2020;13:1325-1336